Dirk Hose

机构：Gavi, Vrije Universiteit Brussel · ORCID：0000-0003-0806-5223

发表论文 490 篇 · 总被引 13833 次 · h-index 63

代表论文

• Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials (2025 · Journal of Clinical Oncology · 被引 40)
• Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma (2024 · Journal of Hematology & Oncology · 被引 3)
• Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation (2024 · JCO Precision Oncology · 被引 2)
• CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study (2024 · Leukemia · 被引 2)
• Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma—Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries (2024 · International Journal of Molecular Sciences · 被引 1)
• Correction: CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma (2026 · Molecular Cancer)